Bulk Pharmaceutical API Sources for HYSINGLA ER

Bulk Pharmaceutical API Sources for HYSINGLA ER

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		H4516_SIGMA
ChemMol		49416051
Chembase.cn		153412

Bulk Active Pharmaceutical Ingredient (API) Sources for: HYSINGLA ER

Last updated: July 28, 2025

Introduction

HYSINGLA ER (hydrocodone bitartrate) is an extended-release formulation of hydrocodone, an opioid analgesic used for managing severe pain. As a Schedule II controlled substance, the quality and sourcing of its active pharmaceutical ingredient (API) are critical to ensure safety, efficacy, regulatory compliance, and supply chain integrity. This article delineates the primary sources of bulk API for HYSINGLA ER, evaluates key suppliers, and analyzes the global landscape for procurement decisions.

Overview of Hydrocodone API Manufacturing

Hydrocodone API synthesis typically involves the extraction and modification of the codeine or thebaine components derived from opium poppy (Papaver somniferum). The manufacturing ecosystem is complex, often involving controlled environments, multiple purification steps, and strict adherence to Good Manufacturing Practices (GMP). Globally, API producers for hydrocodone operate primarily in regulated markets, including the United States, Europe, and parts of Asia.

Major API Sources for Hydrocodone Bitartrate

1. United States

In the U.S., the manufacture and distribution of hydrocodone API are heavily regulated by the Drug Enforcement Administration (DEA). Key domestic manufacturers include:

• Mallinckrodt Pharmaceuticals: Historically, Mallinckrodt has been one of the leading suppliers of hydrocodone API, committing to stringent quality standards and compliance with regulatory authorities. Their manufacturing facilities are certified under the US FDA’s current Good Manufacturing Practice (cGMP) guidelines.

• Amneal Pharmaceuticals: A notable API producer with a focus on North American markets, Amneal manufactures hydrocodone API with compliance to DEA and FDA standards. Their vertically integrated supply chain ensures quality control and timely delivery.

• Qualitest Pharmaceuticals: Operating under Endo International, Qualitest has historically supplied APIs, including hydrocodone, primarily for generic formulations. Their manufacturing processes are validated to meet U.S. quality benchmarks.

2. European Union

In Europe, the API sourcing for hydrocodone is less prominent due to regulatory restrictions in the EU related to opioid production. However, several European-based API manufacturers supply hydrocodone to U.S. and international markets:

• Cespa S.A. (Spain): An established player in opioid API synthesis, Cespa operates facilities compliant with EMA regulations, and supplies hydrocodone API under strict quality protocols.

• Braine-L’Alleud-based API suppliers: European companies with specialized manufacturing for opioid APIs, leveraging advanced purification technologies to ensure high purity levels critical for controlled substances.

3. Asian Manufacturers

Asian API manufacturers play a noteworthy role owing to cost advantages, capacity expansion, and emerging regulatory enhancements:

• Hubei Kangjian Pharmaceutical Co., Ltd. (China): A leading Chinese API producer with GMP certifications, supplying hydrocodone API to North America and other regions. Their manufacturing facilities adhere to domestic and international standards.

• Granules India Ltd. (India): An emerging supplier, Granules India manufactures various controlled substances, including hydrocodone API. They have established quality assurance systems aligned with global compliance requirements.

• Sun Pharmaceutical Industries Ltd. (India): A significant global pharmaceutical entity, Sun Pharma has been expanding its API portfolio to include opioid APIs, emphasizing GMP compliance and scalable production capabilities.

4. Other Notable Suppliers

• Moderna Pharmaceuticals (Mexico): Operates under strict regulatory oversight, providing API to North American markets, with a focus on traceability and GMP adherence.

• Siegfried AG (Switzerland): Known for high-quality APIs, Siegfried offers custom synthesis services and operates within strict regulatory frameworks suitable for Schedule II substances.

Criteria for Selecting API Suppliers

When sourcing APIs for HYSINGLA ER, pharmaceutical companies prioritize several factors:

• Regulatory Compliance: Suppliers must adhere to cGMP, DEA, EMA, and other relevant standards.
• Supply Chain Reliability: Consistent supply volume, logistical stability, and contingency planning.
• Quality Assurance: Purity, residual solvent levels, endotoxin levels, and validation reports.
• Cost and Lead Time: Competitive pricing without compromising quality, with reliable delivery timelines.
• Transparency and Traceability: Full supply chain visibility and documentation to facilitate regulatory audits.

Global Regulatory Challenges and Trends

Manufacturers and suppliers face evolving regulations, including stricter control measures for opioid APIs to prevent diversion and misuse. The DEA’s quota system in the U.S., EU licensing requirements, and import/export controls in Asia influence sourcing strategies. Additionally, transparency initiatives and track-and-trace regulations are increasingly restricting opaque supply chains.

The opioid crisis has prompted heightened scrutiny, prompting companies to bolster quality controls and supply chain integrity. This climate favors established, well-regulated suppliers with proven compliance histories.

Implications for Pharmaceutical Companies

The procurement of hydrocodone API necessitates strategic partnerships with reputable suppliers compliant with international standards. Given the controlled nature of hydrocodone, companies should prioritize vendors with robust regulatory track records and deep manufacturing expertise. Diversifying sources across geographies mitigates risks related to regulatory changes, geopolitical issues, and supply disruptions.

Conclusion

The primary bulk API sources for HYSINGLA ER primarily encompass manufacturers in North America, Europe, and Asia, with a strong emphasis on compliance with regulatory frameworks governing controlled substances. The landscape is dominated by established players such as Mallinckrodt, Amneal, Cespa, and high-quality Asian producers like Hubei Kangjian and Granules India. Ensuring quality and regulatory adherence remains paramount, especially given the opioid's potential for misuse.

Key Takeaways

• Multiple reputable suppliers across North America, Europe, and Asia provide hydrocodone API, each with unique strengths.
• Regulatory compliance and supply chain reliability are critical criteria for API procurement, especially for Schedule II opioids.
• Asian manufacturers are increasingly significant due to capacity and cost advantages, but require rigorous due diligence to confirm compliance.
• Global regulatory developments and scrutiny necessitate transparent, traceable supply chains backed by robust quality assurance.
• Strategic sourcing from approved and compliant suppliers ensures steady supply, regulatory compliance, and minimization of diversion risks.

---

FAQs

1. What are the primary regulatory considerations when sourcing hydrocodone API?
Manufacturers must adhere to cGMP standards, DEA regulations in the U.S., EMA guidelines in Europe, and import/export controls. Transparency, traceability, and validation documentation are essential for compliance and audit readiness.

2. How do supply chain disruptions impact the sourcing of hydrocodone API?
Disruptions—due to regulatory changes, geopolitical tensions, or manufacturing issues—can cause shortages. Diversifying suppliers across regions and maintaining safety stock mitigate risks.

3. Are Chinese or Indian API manufacturers compliant with U.S. and European regulations?
Many Chinese and Indian API producers operate under GMP certifications aligned with international standards. However, rigorous verification and audit processes are necessary before engagement.

4. How do quality standards differ among international API suppliers?
While cGMP compliance is a baseline, specifics such as residual solvents, endotoxin levels, and impurities must meet country-specific pharmacopeial standards, influencing selection criteria.

5. What future trends are likely to influence API sourcing for opioids like hydrocodone?
Increased regulatory oversight, push for transparency, and efforts to prevent misuse will likely lead to stricter licensing, enhanced traceability, and preference for suppliers with strong compliance histories.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Current Good Manufacturing Practice for Finished Pharmaceuticals.
[2] Drug Enforcement Administration. (2023). Controlled Substances Schedules.
[3] European Medicines Agency. (2021). Guidelines on Good Manufacturing Practice.
[4] Suppliers’ websites and official certifications.
[5] Industry reports and market analyses on opioid API manufacturing.